Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Hirva Mamdani(Wayne State University), Shadia I. Jalal(Indiana University Health), Heather Burney(Indiana University – Purdue University Indianapolis), Bryan J. Schneider(Georgetown University), Thomas J. Birdas(Indiana University – Purdue University Indianapolis), Tracy M. Watkins(Indiana University – Purdue University Indianapolis), Pashtoon Murtaza Kasi(Cornell University), Laith Abushahin(The Ohio State University), Sunil Badve(Emory University), Kenneth A. Kesler(Indiana University – Purdue University Indianapolis), Susan M. Perkins(Indiana University School of Medicine)
Cited by 0
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
|Journal of Clinical Oncology|2014|1.3k
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
|JAMA|2018|580
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560